Research programme: nerve-targeted gene therapy - Periphagen

Drug Profile

Research programme: nerve-targeted gene therapy - Periphagen

Alternative Names: NC 3; NE 2; NE2 Endomorphin; NG 2; NG2 GAD; NN1 Neurotrophin

Latest Information Update: 05 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Diamyd Medical
  • Developer Diamyd Medical; Periphagen Holdings; University of Michigan
  • Class Gene therapies
  • Mechanism of Action GABA modulators; Glutamate decarboxylase stimulants; Nerve growth factor stimulants; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Neuropathic pain
  • Research Peripheral nervous system diseases
  • No development reported Erectile dysfunction; Glioma

Most Recent Events

  • 12 Oct 2012 Preclinical development is ongoing for Neuropathic pain in USA
  • 01 Sep 2012 Periphagen Holdings acquires Diamyd Inc.
  • 12 Sep 2011 Diamyd Inc. and the University of Michigan receive a grant from the National Institutes of Health for Nerve-targeted gene therapy development for prevention of chemotherapy-induced Peripheral nerve disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top